784-57-6

Usage

Uses

2-(4-Morpholinyl)-5-(trifluoromethyl)aniline is used as pharmaceutical intermediate.

InChI:InChI=1/C11H13F3N2O/c12-11(13,14)8-1-2-10(9(15)7-8)16-3-5-17-6-4-16/h1-2,7H,3-6,15H2

Upstream product

• 756833-07-5 N-[2-(morpholinyl)-5-(trifluoromethyl)phenyl]-2-pyridinecarboxamide 
• 61350-01-4 N-[3-(trifluoromethyl)phenyl]-2-pyridinecarboxamide 
• 98-08-8 α,α,α-trifluorotoluene 
• 98-16-8 3-trifluoromethylaniline 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 
• 62054-72-2 4-(2-nitro-4-trifluoromethylphenyl)morpholine 

Downstream Products

• 870221-11-7 3-hydroxy-4-methyl-N-(2-morpholin-4-yl-5-trifluoromethyl-phenyl)-benzamide 
• 131679-48-6 2-morpholino-5-trifluoromethylphenyl isothiocyanate 
• 69259-39-8 N-(2-morpholin-4-yl-5-trifluoromethyl-phenyl)-acetamide 
• 1028338-74-0 1,4-dichloro-phthalazine-6-carboxylic acid (2-morpholin-4-yl-5-trifluoromethyl-phenyl)-amide 
• 1253379-97-3 1-[(2-chloro-4-fluorophenyl)methyl]-4-[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-2,3-piperazinedione 
• 1309358-69-7 N-[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-1-phenylcyclopropanecarboxamide 
• 1338383-80-4 2-isopropyl-3-[2-morpholino-5-(trifluoromethyl)phenylamino]-7H-furo[3,2-g]chromen-7-one 
• 446052-25-1 N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide 
• 924257-06-7 N-(2-morpholinyl-5-trifluoromethylphenyl)-2-(3-methylphenoxy)propanamide 
• 848057-98-7 5-methyl-N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]furan-2-carboxamide 

Relevant academic research and scientific papers

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.

Novel pyrazole amide compound and preparation thereof, and application of novel pyrazole amide compound in prevention and treatment of plant pathogenic diseases and pest killing

The invention relates to a novel pyrazole amide compound I and a preparation method thereof and application of the novel pyrazole amide compound I in prevention and treatment of plant pathogenic disease and pest killing. The novel pyrazole amide compound

Copper-catalyzed: Ortho -C(sp2)-H amination of benzamides and picolinamides with alkylamines using oxygen as a green oxidant

A versatile Cu-catalyzed direct ortho-C(sp2)-H amination of benzamides and picolinamides with alkylamines has been achieved. This method employs cheap and eco-friendly copper as a catalyst and oxygen as an oxidant, and also has the advantages of straightf

A N - (2 - morpholinyl -5 - trifluoromethyl phenyl) -2 - (3 - methylphenoxy) propionamide preparation method (by machine translation)

The invention discloses a N - (2 - morpholinyl - 5 - trifluoromethyl-phenyl) - 2 - (3 - methylphenoxy) propionamide of the preparation method, comprises the following steps: The invention provides N - (2 - morpholinyl - 5 - trifluoromethyl-phenyl) - 2 -

Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs)

The serine/arginine-rich protein kinases (SRPKs) have frequently been found with altered activity in a number of cancers, suggesting they could serve as potential therapeutic targets in oncology. Here we describe the synthesis of a series of twenty-two tr

METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT

The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhi

(Aminophenyl)morpholines and use thereof

(2-Aminophenyl)morpholine compounds having a haloalkyl, lower alkylsulfonyl, halo-lower alkylsulfonyl, or branched-chain alkyl substituent on the aromatic ring para to the morpholino nitrogen. The compounds are useful as herbicides and may be used as inte

Herbicidal morpholinobenzimidazoles

Tricyclic 1,2-morpholinobenzimidazoles having a haloalkyl, alkylsulfonyl, haloalkylsulfonyl, halo or lower alkyl substituent on the aromatic ring para to the morpholino nitrogen. The aromatic ring and morpholino ring may also have other substituents. The